SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Retz, Margitta; Bedke, Jens; Boegemann, Martin; Grimm, Marc-Oliver; Zimmermann, Uwe; Mueller, Lothar; Leiber, Christian; Teber, Dogu; Wirth, Manfred; Bolenz, Christian; van Alphen, Robbert; De Santis, Maria; Beeker, Aart; Lehmann, Jan; Indorf, Martin; Frank, Melanie; Bokemeyer, Carsten; Gschwend, Juergen E.

dc.contributor.author	Bedke, Jens
dc.date.accessioned	2020-06-23T14:15:14Z
dc.date.available	2020-06-23T14:15:14Z
dc.date.issued	2019
dc.identifier.issn	1879-0852
dc.identifier.uri	http://hdl.handle.net/10900/101788
dc.language.iso	en	de_DE
dc.publisher	Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.ejca.2018.11.001	de_DE
dc.subject.ddc	610	de_DE
dc.title	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_03307
utue.publikation.seiten	37-45	de_DE
utue.personen.roh	Retz, Margitta
utue.personen.roh	Bedke, Jens
utue.personen.roh	Boegemann, Martin
utue.personen.roh	Grimm, Marc-Oliver
utue.personen.roh	Zimmermann, Uwe
utue.personen.roh	Mueller, Lothar
utue.personen.roh	Leiber, Christian
utue.personen.roh	Teber, Dogu
utue.personen.roh	Wirth, Manfred
utue.personen.roh	Bolenz, Christian
utue.personen.roh	van Alphen, Robbert
utue.personen.roh	De Santis, Maria
utue.personen.roh	Beeker, Aart
utue.personen.roh	Lehmann, Jan
utue.personen.roh	Indorf, Martin
utue.personen.roh	Frank, Melanie
utue.personen.roh	Bokemeyer, Carsten
utue.personen.roh	Gschwend, Juergen E.
dcterms.isPartOf.ZSTitelID	European Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Volume	107	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE